Cargando…
An optimised dosing regimen versus a standard dosing regimen of vancomycin for the treatment of late onset sepsis due to Gram-positive microorganisms in neonates and infants aged less than 90 days (NeoVanc): study protocol for a randomised controlled trial
BACKGROUND: Vancomycin has been used in clinical practice for over 50 years; however, validated, pharmacokinetic (PK) data relating clinical outcomes to different dosing regimens in neonates are lacking. Coagulase negative staphylococci (CoNS) are the most commonly isolated organisms in neonatal, la...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7158076/ https://www.ncbi.nlm.nih.gov/pubmed/32293527 http://dx.doi.org/10.1186/s13063-020-4184-8 |
_version_ | 1783522465351204864 |
---|---|
author | Hill, Louise F. Turner, Mark A. Lutsar, Irja Heath, Paul T. Hardy, Pollyanna Linsell, Louise Jacqz-Aigrain, Evelyne Roilides, Emmanuel Sharland, Mike |
author_facet | Hill, Louise F. Turner, Mark A. Lutsar, Irja Heath, Paul T. Hardy, Pollyanna Linsell, Louise Jacqz-Aigrain, Evelyne Roilides, Emmanuel Sharland, Mike |
author_sort | Hill, Louise F. |
collection | PubMed |
description | BACKGROUND: Vancomycin has been used in clinical practice for over 50 years; however, validated, pharmacokinetic (PK) data relating clinical outcomes to different dosing regimens in neonates are lacking. Coagulase negative staphylococci (CoNS) are the most commonly isolated organisms in neonatal, late-onset sepsis (LOS). Optimised use to maximise efficacy while minimising toxicity and resistance selection is imperative to ensure vancomycin’s continued efficacy. METHODS: NeoVanc is a European, open-label, Phase IIb, randomised, controlled, non-inferiority trial comparing an optimised vancomycin regimen to a standard vancomycin regimen when treating LOS known/suspected to be caused by Gram-positive organisms (excluding Staphylococcus aureus) in infants aged ≤ 90 days. Three hundred infants will be recruited and randomised in a 1:1 ratio. Infants can be recruited if they have culture confirmed (a positive culture from a normally sterile site and at least one clinical/laboratory criterion) or clinical sepsis (presence of any ≥ 3 clinical/laboratory criteria) in the 24 h before randomisation. The optimised regimen consists of a vancomycin loading dose (25 mg/kg) followed by 5 ± 1 days of 15 mg/kg q12h or q8h, dependent on postmenstrual age (PMA). The standard regimen is a 10 ± 2 day vancomycin course at 15 mg/kg q24h, q12h or q8h, dependent on PMA. The primary endpoint is a successful outcome at the test of cure visit (10 ± 1 days after the end of vancomycin therapy). A successful outcome consists of the patient being alive, having successfully completed study vancomycin therapy and having not had a clinical/microbiological relapse/new infection requiring treatment with vancomycin or other anti-staphylococcal antibiotic for > 24 h. Secondary endpoints include clinical/microbiological relapse/new infection at the short-term follow-up visit (30 ± 5 days after the initiation of vancomycin), evaluation of safety (renal/hearing), vancomycin PK and assessment of a host biomarker panel over the course of vancomycin therapy. DISCUSSION: Based on previous pre-clinical data and a large meta-analysis of neonatal, PK/pharmacodynamic data, NeoVanc was set up to provide evidence on whether a loading dose followed by a short vancomycin course is non-inferior, regarding efficacy, when compared to a standard, longer course. If non-inferiority is demonstrated, this would support adoption of the optimised regimen as a way of safely reducing vancomycin exposure when treating neonatal, Gram-positive LOS. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02790996. Registered on 7 April 2016. EudraCT, 2015–000203-89. Entered on 18 July 2016. |
format | Online Article Text |
id | pubmed-7158076 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-71580762020-04-21 An optimised dosing regimen versus a standard dosing regimen of vancomycin for the treatment of late onset sepsis due to Gram-positive microorganisms in neonates and infants aged less than 90 days (NeoVanc): study protocol for a randomised controlled trial Hill, Louise F. Turner, Mark A. Lutsar, Irja Heath, Paul T. Hardy, Pollyanna Linsell, Louise Jacqz-Aigrain, Evelyne Roilides, Emmanuel Sharland, Mike Trials Study Protocol BACKGROUND: Vancomycin has been used in clinical practice for over 50 years; however, validated, pharmacokinetic (PK) data relating clinical outcomes to different dosing regimens in neonates are lacking. Coagulase negative staphylococci (CoNS) are the most commonly isolated organisms in neonatal, late-onset sepsis (LOS). Optimised use to maximise efficacy while minimising toxicity and resistance selection is imperative to ensure vancomycin’s continued efficacy. METHODS: NeoVanc is a European, open-label, Phase IIb, randomised, controlled, non-inferiority trial comparing an optimised vancomycin regimen to a standard vancomycin regimen when treating LOS known/suspected to be caused by Gram-positive organisms (excluding Staphylococcus aureus) in infants aged ≤ 90 days. Three hundred infants will be recruited and randomised in a 1:1 ratio. Infants can be recruited if they have culture confirmed (a positive culture from a normally sterile site and at least one clinical/laboratory criterion) or clinical sepsis (presence of any ≥ 3 clinical/laboratory criteria) in the 24 h before randomisation. The optimised regimen consists of a vancomycin loading dose (25 mg/kg) followed by 5 ± 1 days of 15 mg/kg q12h or q8h, dependent on postmenstrual age (PMA). The standard regimen is a 10 ± 2 day vancomycin course at 15 mg/kg q24h, q12h or q8h, dependent on PMA. The primary endpoint is a successful outcome at the test of cure visit (10 ± 1 days after the end of vancomycin therapy). A successful outcome consists of the patient being alive, having successfully completed study vancomycin therapy and having not had a clinical/microbiological relapse/new infection requiring treatment with vancomycin or other anti-staphylococcal antibiotic for > 24 h. Secondary endpoints include clinical/microbiological relapse/new infection at the short-term follow-up visit (30 ± 5 days after the initiation of vancomycin), evaluation of safety (renal/hearing), vancomycin PK and assessment of a host biomarker panel over the course of vancomycin therapy. DISCUSSION: Based on previous pre-clinical data and a large meta-analysis of neonatal, PK/pharmacodynamic data, NeoVanc was set up to provide evidence on whether a loading dose followed by a short vancomycin course is non-inferior, regarding efficacy, when compared to a standard, longer course. If non-inferiority is demonstrated, this would support adoption of the optimised regimen as a way of safely reducing vancomycin exposure when treating neonatal, Gram-positive LOS. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02790996. Registered on 7 April 2016. EudraCT, 2015–000203-89. Entered on 18 July 2016. BioMed Central 2020-04-15 /pmc/articles/PMC7158076/ /pubmed/32293527 http://dx.doi.org/10.1186/s13063-020-4184-8 Text en © The Author(s). 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Study Protocol Hill, Louise F. Turner, Mark A. Lutsar, Irja Heath, Paul T. Hardy, Pollyanna Linsell, Louise Jacqz-Aigrain, Evelyne Roilides, Emmanuel Sharland, Mike An optimised dosing regimen versus a standard dosing regimen of vancomycin for the treatment of late onset sepsis due to Gram-positive microorganisms in neonates and infants aged less than 90 days (NeoVanc): study protocol for a randomised controlled trial |
title | An optimised dosing regimen versus a standard dosing regimen of vancomycin for the treatment of late onset sepsis due to Gram-positive microorganisms in neonates and infants aged less than 90 days (NeoVanc): study protocol for a randomised controlled trial |
title_full | An optimised dosing regimen versus a standard dosing regimen of vancomycin for the treatment of late onset sepsis due to Gram-positive microorganisms in neonates and infants aged less than 90 days (NeoVanc): study protocol for a randomised controlled trial |
title_fullStr | An optimised dosing regimen versus a standard dosing regimen of vancomycin for the treatment of late onset sepsis due to Gram-positive microorganisms in neonates and infants aged less than 90 days (NeoVanc): study protocol for a randomised controlled trial |
title_full_unstemmed | An optimised dosing regimen versus a standard dosing regimen of vancomycin for the treatment of late onset sepsis due to Gram-positive microorganisms in neonates and infants aged less than 90 days (NeoVanc): study protocol for a randomised controlled trial |
title_short | An optimised dosing regimen versus a standard dosing regimen of vancomycin for the treatment of late onset sepsis due to Gram-positive microorganisms in neonates and infants aged less than 90 days (NeoVanc): study protocol for a randomised controlled trial |
title_sort | optimised dosing regimen versus a standard dosing regimen of vancomycin for the treatment of late onset sepsis due to gram-positive microorganisms in neonates and infants aged less than 90 days (neovanc): study protocol for a randomised controlled trial |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7158076/ https://www.ncbi.nlm.nih.gov/pubmed/32293527 http://dx.doi.org/10.1186/s13063-020-4184-8 |
work_keys_str_mv | AT hilllouisef anoptimiseddosingregimenversusastandarddosingregimenofvancomycinforthetreatmentoflateonsetsepsisduetogrampositivemicroorganismsinneonatesandinfantsagedlessthan90daysneovancstudyprotocolforarandomisedcontrolledtrial AT turnermarka anoptimiseddosingregimenversusastandarddosingregimenofvancomycinforthetreatmentoflateonsetsepsisduetogrampositivemicroorganismsinneonatesandinfantsagedlessthan90daysneovancstudyprotocolforarandomisedcontrolledtrial AT lutsarirja anoptimiseddosingregimenversusastandarddosingregimenofvancomycinforthetreatmentoflateonsetsepsisduetogrampositivemicroorganismsinneonatesandinfantsagedlessthan90daysneovancstudyprotocolforarandomisedcontrolledtrial AT heathpault anoptimiseddosingregimenversusastandarddosingregimenofvancomycinforthetreatmentoflateonsetsepsisduetogrampositivemicroorganismsinneonatesandinfantsagedlessthan90daysneovancstudyprotocolforarandomisedcontrolledtrial AT hardypollyanna anoptimiseddosingregimenversusastandarddosingregimenofvancomycinforthetreatmentoflateonsetsepsisduetogrampositivemicroorganismsinneonatesandinfantsagedlessthan90daysneovancstudyprotocolforarandomisedcontrolledtrial AT linselllouise anoptimiseddosingregimenversusastandarddosingregimenofvancomycinforthetreatmentoflateonsetsepsisduetogrampositivemicroorganismsinneonatesandinfantsagedlessthan90daysneovancstudyprotocolforarandomisedcontrolledtrial AT jacqzaigrainevelyne anoptimiseddosingregimenversusastandarddosingregimenofvancomycinforthetreatmentoflateonsetsepsisduetogrampositivemicroorganismsinneonatesandinfantsagedlessthan90daysneovancstudyprotocolforarandomisedcontrolledtrial AT roilidesemmanuel anoptimiseddosingregimenversusastandarddosingregimenofvancomycinforthetreatmentoflateonsetsepsisduetogrampositivemicroorganismsinneonatesandinfantsagedlessthan90daysneovancstudyprotocolforarandomisedcontrolledtrial AT sharlandmike anoptimiseddosingregimenversusastandarddosingregimenofvancomycinforthetreatmentoflateonsetsepsisduetogrampositivemicroorganismsinneonatesandinfantsagedlessthan90daysneovancstudyprotocolforarandomisedcontrolledtrial AT anoptimiseddosingregimenversusastandarddosingregimenofvancomycinforthetreatmentoflateonsetsepsisduetogrampositivemicroorganismsinneonatesandinfantsagedlessthan90daysneovancstudyprotocolforarandomisedcontrolledtrial AT hilllouisef optimiseddosingregimenversusastandarddosingregimenofvancomycinforthetreatmentoflateonsetsepsisduetogrampositivemicroorganismsinneonatesandinfantsagedlessthan90daysneovancstudyprotocolforarandomisedcontrolledtrial AT turnermarka optimiseddosingregimenversusastandarddosingregimenofvancomycinforthetreatmentoflateonsetsepsisduetogrampositivemicroorganismsinneonatesandinfantsagedlessthan90daysneovancstudyprotocolforarandomisedcontrolledtrial AT lutsarirja optimiseddosingregimenversusastandarddosingregimenofvancomycinforthetreatmentoflateonsetsepsisduetogrampositivemicroorganismsinneonatesandinfantsagedlessthan90daysneovancstudyprotocolforarandomisedcontrolledtrial AT heathpault optimiseddosingregimenversusastandarddosingregimenofvancomycinforthetreatmentoflateonsetsepsisduetogrampositivemicroorganismsinneonatesandinfantsagedlessthan90daysneovancstudyprotocolforarandomisedcontrolledtrial AT hardypollyanna optimiseddosingregimenversusastandarddosingregimenofvancomycinforthetreatmentoflateonsetsepsisduetogrampositivemicroorganismsinneonatesandinfantsagedlessthan90daysneovancstudyprotocolforarandomisedcontrolledtrial AT linselllouise optimiseddosingregimenversusastandarddosingregimenofvancomycinforthetreatmentoflateonsetsepsisduetogrampositivemicroorganismsinneonatesandinfantsagedlessthan90daysneovancstudyprotocolforarandomisedcontrolledtrial AT jacqzaigrainevelyne optimiseddosingregimenversusastandarddosingregimenofvancomycinforthetreatmentoflateonsetsepsisduetogrampositivemicroorganismsinneonatesandinfantsagedlessthan90daysneovancstudyprotocolforarandomisedcontrolledtrial AT roilidesemmanuel optimiseddosingregimenversusastandarddosingregimenofvancomycinforthetreatmentoflateonsetsepsisduetogrampositivemicroorganismsinneonatesandinfantsagedlessthan90daysneovancstudyprotocolforarandomisedcontrolledtrial AT sharlandmike optimiseddosingregimenversusastandarddosingregimenofvancomycinforthetreatmentoflateonsetsepsisduetogrampositivemicroorganismsinneonatesandinfantsagedlessthan90daysneovancstudyprotocolforarandomisedcontrolledtrial AT optimiseddosingregimenversusastandarddosingregimenofvancomycinforthetreatmentoflateonsetsepsisduetogrampositivemicroorganismsinneonatesandinfantsagedlessthan90daysneovancstudyprotocolforarandomisedcontrolledtrial |